| Study (lead author) |
No. Treated Patients |
Delivery Route |
Treatment Duration (mo) |
Mean PSA Change (ng/mL) |
No. With Cancer |
|
| Tenover (1992) |
13 |
IM |
3 |
0.6 |
0 |
| Sih et al (1997) |
10 |
IM |
12 |
0.7 |
0 |
| Hajjar et al (1997) |
26 |
IM |
24 |
0.49 |
0 |
| Svetec et al (1997) |
48 |
IM |
12.8 |
0.29 |
0 |
| Guay et al (2000) |
16 |
Patch |
3 |
0.2 |
3 |
|
25 |
IM |
3 |
0.63 |
(overall) |
|
48 |
Clomiphene |
3 |
1.0 |
|
| Snyder et al (1999) |
54 |
Patch |
36 |
0.6 |
1 |
| Present study: all time points |
54 |
IM |
30.2 |
0.96 |
1 |
| More than 36 mo only (subset) |
19 |
IM |
58.5 |
0.59 |
0 |
|
| *IM indicates intramuscular; PSA, prostate-specific antigen. |
|
